PFE · 8-K · 20261103PR000125
Net Income and Profitability
PFIZER INC · 2026-11-03 · Importance 58 · Surprise 56 · From source text
Third-quarter reported net income attributable to Pfizer shareholders decreased 8% to $3.242 billion, and reported diluted EPS fell 9% to $0.56. Nine-month net income declined 40% to $5.681 billion and reported diluted EPS fell 40% to $0.99. Nine-month other income/deductions included $4.325 billion of asset impairment charges, primarily a $3.8 billion impairment of sigvotatug vedotin IPR&D and a $525 million Oxbryta developed-technology impairment, partly offset by a $1.870 billion gain on the sale of Pfizer’s ViiV investment. Nine-month reported other deductions also included $1.047 billion for certain legal matters.
Key facts
- Pfizer’s reported net income was $3.242 billion in third-quarter 2026, versus $3.541 billion in third-quarter 2025, an 8% decrease. source
- Pfizer’s adjusted income was $4.985 billion in third-quarter 2026, versus $4.949 billion in third-quarter 2025, a 1% increase. source
- Pfizer’s reported diluted EPS was $0.56 in third-quarter 2026, versus $0.62 in third-quarter 2025, a 9% decrease. source
- Pfizer’s adjusted diluted EPS was $0.87 in both third-quarter 2026 and third-quarter 2025. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | negative | realized | -2.0% | Pfizer’s reported net income was $3.242 billion in third-quarter 2026, versus $3.541 billion in third-quarter 2025, an 8% decrease. |
| net_income | positive | realized | +0.2% | Pfizer’s adjusted income was $4.985 billion in third-quarter 2026, versus $4.949 billion in third-quarter 2025, a 1% increase. |